Immunotherapy: Personalized Treatment for Advanced Prostate Cancer - OncLive | Immunopathology & Immunotherapy | Scoop.it
From www.onclive.com - September 23, 2012 8:39 AM
Immunotherapy: Personalized Treatment for Advanced Prostate CancerOncLiveThis white paper focuses on the new immunotherapy, Provenge.

In April 2010, the US Food and Drug Administration approved sipuleucel-T (Provenge®, Dendreon Corporation), an immune therapy and the first treatment for pre-chemotherapy use. Patients with castration-resistant and metastatic disease now had a treatment that would help the body fight its own cancer. This white paper focuses on the new immunotherapy, Provenge.